These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3376184)

  • 21. Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
    Wieloch M; Hillarp A; Strandberg K; Nilsson C; Svensson PJ
    Thromb Res; 2009 Jul; 124(3):344-8. PubMed ID: 19423152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two methods for INR determination in a pharmacist-based oral anticoagulation clinic.
    Yamreudeewong W; Johnson JV; Cassidy TG; Berg JT
    Pharmacotherapy; 1996; 16(6):1159-65. PubMed ID: 8947990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.
    D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M
    Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements.
    Weiss P; Halkin H; Almog S
    Thromb Haemost; 1986 Dec; 56(3):371-5. PubMed ID: 3563968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of influenza vaccine in patients receiving long-term warfarin therapy.
    Weibert RT; Lorentz SM; Norcross WA; Klauber MR; Jagger PI
    Clin Pharm; 1986 Jun; 5(6):499-503. PubMed ID: 3720216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cranberry does not affect prothrombin time in male subjects on warfarin.
    Li Z; Seeram NP; Carpenter CL; Thames G; Minutti C; Bowerman S
    J Am Diet Assoc; 2006 Dec; 106(12):2057-61. PubMed ID: 17126638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose oral anticoagulation and antiplatelet therapy with St. Jude Medical heart valve prosthesis.
    Yamak B; Iscan Z; Mavitas B; Ulus AT; Katircioglu SF; Tasdemir O; Bayazit K
    J Heart Valve Dis; 1999 Nov; 8(6):665-73. PubMed ID: 10616246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolongation of prothrombin time with the use of indomethacin and warfarin.
    Chan TY
    Br J Clin Pract; 1997; 51(3):177-8. PubMed ID: 9293062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.
    White RH; Hong R; Venook AP; Daschbach MM; Murray W; Mungall DR; Coleman RW
    J Gen Intern Med; 1987; 2(3):141-8. PubMed ID: 3295148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictability of the warfarin maintenance dosage based on the initial response.
    McGhee JR; Evans R; Wolfson PM; Dunlap S; Haspel L; Smith CR; Braunstein DB
    J Am Osteopath Assoc; 1981 Jan; 80(5):335-9. PubMed ID: 7462045
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).
    Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S
    Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats.
    Cao YG; Liu XQ; Chen YC; Hao K; Wang GJ
    Eur J Pharm Sci; 2007 Feb; 30(2):175-80. PubMed ID: 17169538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral anticoagulant therapy: analysis of the efficacy of a dosage guide].
    Jobin F; Vigneault M
    CMAJ; 1986 Jul; 135(2):123-7. PubMed ID: 3719497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
    Crowther MA
    Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in the pharmacology of warfarin during long-term administration in dogs.
    Covell DG; Abbrecht PH; Powers WF
    J Lab Clin Med; 1984 Feb; 103(2):272-83. PubMed ID: 6693797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal initial dose adjustment of warfarin in orthopedic patients.
    Lenzini PA; Grice GR; Milligan PE; Gatchel SK; Deych E; Eby CS; Burnett RS; Clohisy JC; Barrack RL; Gage BF
    Ann Pharmacother; 2007 Nov; 41(11):1798-804. PubMed ID: 17911206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pocket calculator program for prediction of warfarin maintenance dose.
    Canaday BR; Sawyer WT
    Comput Biol Med; 1982; 12(2):179-87. PubMed ID: 7105664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.